Table 2.
RVC permeation parameters of NLCs and solution (mean±SD, n=3)
| Formulations | P72 (μg· cm−2) | Kp (cm· h−1) | Jss (μg· cm−2· h−1) |
|---|---|---|---|
| HA-TPGS-RVC/DMDT-NLCs | 1018.3±39.1 | 7.2×10−3 | 14.2 |
| HA-TPGS-RVC-NLCs | 989.4±31.9 | 7.0×10−3 | 13.8 |
| TPGS-RVC/DMDT-NLCs | 666.8±18.7 | 4.7×10−3 | 9.3 |
| RVC/DMDT-NLCs | 439.2±17.3 | 3.1×10−3 | 6.1 |
| RVC/DMDT SOLU | 214.3±13.2 | 1.5×10−3 | 3.0 |
Abbreviations: HA, hyaluronic acid; TPGS, tocopheryl polyethylene glycol 1000 succinate; RVC, ropivacaine; DMDT, dexmedetomidine; NLCs, nanostructured lipid carriers; P72, the cumulative amount of drugs penetrated at 72 hrs; Jss, steady-state fluxes; Kp, permeability coefficient.